A phase I/II study to evaluate the safety and preliminary activity of Zarnestra (R115777, tipifarnib) in combination with low dose Ara-C (LDAC) [cytarabine] in patients with myelodysplastic syndrome (MDS) and AML [acute myeloid leukaemia]

Trial Profile

A phase I/II study to evaluate the safety and preliminary activity of Zarnestra (R115777, tipifarnib) in combination with low dose Ara-C (LDAC) [cytarabine] in patients with myelodysplastic syndrome (MDS) and AML [acute myeloid leukaemia]

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2014

At a glance

  • Drugs Tipifarnib (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2014 Status changed from recruiting to discontinued, as per M.D. Anderson Cancer Center record.
    • 07 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top